Guided by scientific and clinical intelligence, Inmagene uses cutting-edge bioengineering technology to develop a new generation of drugs to address unmet medical needs in inflammatory and immunological diseases. Inmagene’s clinical stage drug candidates, IMG-007, IMG-004 and IMG-008, have been designed to have the following characteristics:

• long acting (based on extended half-life and/or durable pharmacodynamic effect)
• wide therapeutic window (based on enhanced potency and reduced safety risk)